This dynamic CME program blends interactive case consultations with a data-driven deep dive into long-acting injectables (LAIs) for schizophrenia. Through engaging real-world scenarios, learners will explore barriers and biases that influence LAI utilization and discover communication strategies that foster shared decision-making with patients and caregivers. A comprehensive evidence review highlights innovative LAIs, their attributes, and the latest clinical trial findings, offering practical insights for treatment planning. This unique format equips clinicians with both the knowledge and the skills to optimize adherence, improve outcomes, and confidently integrate LAIs into patient care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 523 Route 303
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Virtual patient / simulation
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedNov 25, 2025
-
Last day to claim creditNov 26, 2026 7 weeks left
-
Physicians’ Education Resource Integrating Motivational Interviewing Techniques to Overcome Barriers to the Use of a Long-Acting Injectable Agent in Patients With Schizophrenia
-
Vindico Medical Education, LLC Optimizing Schizophrenia Outcomes Through Early Treatment With Long-Acting Injectables
-
Catamount Medical Education +1 1,800 Seconds in Current Treatment Approaches for Schizophrenia
-
Paradigm Medical Communications, LLC Moving Beyond Injection Burden: Breakthroughs in Sustained Retinal Delivery
-
Paradigm Medical Communications, LLC Delivering on the Promise of Sustained Treatment: Innovations in Long-Term Disease Control
-
Paradigm Medical Communications, LLC Reading Between the Lines: Nuanced Decision-Making With Sustained Delivery Therapies
